Key highlights
- AVITA Medical (ASX:AVH) shares were priced at $4.36 as at 4:10 pm GMT+11 on 22 October 2026, up 9.27% on the day, with the data showing a gain of 246.03%.
- Its 6 August 2026 results reported record Q2 net Revenue of $21.7 million, up 18% year on year.
- The company raised 2026 revenue guidance to $86–89 million and expects to reach Cash Flow breakeven in the fourth quarter of 2026.
AVITA Medical, Inc. (ASX:AVH) shares were priced at $4.36 as at 4:10 pm GMT+11 on 22 October 2026, up 9.27% (up $0.37) on the day, and the share performance data supplied shows a gain of 246.03%, without stating the period. AVITA is a therapeutic acute wound care company listed on Nasdaq and the ASX. In its second quarter 2026 results, dated 6 August 2026, it reported record revenue and raised its full-year guidance.
About Avita Medical Inc: Business overview
AVITA Medical, Inc. develops and sells products for wound care and skin restoration. Its commercial portfolio is led by the RECELL system, supported by Cohealyx and PermeaDerm, and it also reports international revenue. The company is headquartered in Valencia, California, and is listed on NASDAQ as RCEL and on the ASX as AVH.
Second quarter 2026 results (6 August 2026)
AVITA reported Q2 net revenue of $21.7 million, up 18% year over year and 13% on the previous quarter, driven by RECELL and supported by increasing adoption of Cohealyx and PermeaDerm. Gross Profit Margin was 81.9%, up 70 basis points, and operating expenses were $24.6 million, down 6% year over year.
Net cash use improved to about $3.2 million from $9.9 million in the first quarter, and cash, cash equivalents and marketable securities at quarter end were about $11.1 million.
Guidance, cash flow and reimbursement
The company raised its full-year 2026 net revenue guidance to $86 million to $89 million from $80 million to $85 million, against $71.6 million of revenue in 2025, representing growth of 20% to 24%. It said it expects to reach cash flow breakeven in the fourth quarter of 2026.
AVITA also noted that the Centers for Medicare & Medicaid Services released proposed calendar year 2027 Medicare payment updates for RECELL that, if adopted, would set national physician payment and increase hospital outpatient and ambulatory surgical centre Facility payment rates, and that it expected to present PermeaDerm I study data in August.
Related sector context
Healthcare and medical technology companies are influenced by clinical progress, regulatory pathways, reimbursement decisions and commercial uptake. Earnings reports often include unit sales, revenue growth, cash use and guidance, and regulatory interactions such as meetings with the US FDA are announced when material. Small companies in the sector can see share price movements driven by news flow and funding conditions.
Risks to weigh in
Medical device companies depend on regulatory and reimbursement decisions, including CMS proposals that may change before adoption, and on adoption by hospitals and surgeons. Guidance and cash flow breakeven expectations are forecasts, and cash balances of about $11.1 million leave limited headroom if timing moves. The percentage figure in the share performance data has no stated period, and the share price can move quickly on results and news.
Catalysts on watch
Third quarter 2026 results and progress toward cash flow breakeven in the fourth quarter.
Finalisation of the CMS calendar year 2027 payment rules for RECELL.
Commercial uptake of Cohealyx and PermeaDerm and any updated guidance.
Looking back and ahead
AVITA’s share performance data shows a large percentage gain and a same-day rise, and its latest results describe record revenue, higher guidance and an expected cash flow breakeven. Subsequent reports will show how those expectations are met.
_11_16_2026_07_52_44_870464.jpg)





Please wait processing your request...